# US 2010/0168031 A1 · Lat peptides and their use in assays for identifying immunosuppressants

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168031 A1
- Document ID: US20100168031A1
- Status: Published application
- Kind: A1
- Application number: 10/344,201
- Filed: 2001-08-07
- Published: 2010-07-01
- Earliest claimed: 2000-08-09
- Inventors: Francois Cardinaux
- Web page: https://patentgrep.com/patent/US20100168031A1

## CPC

- C07K 7/06: having 5 to 11 amino acids
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 14/4705: {stimulating, promoting or activating activity}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to novel peptides and their use in assays for identifying novel immunosuppressants. More particularly the present invention provides methods and compositions for identifying compounds that will modulate the interaction of protein tyrosine kinase substrates with their intracellular ligands, as well as between their intracellular ligands and other members of the signaling pathway.

## Claims

### Claim 1

A compound of formula I
R1-Tyr-R2 (I)
wherein
R1 is HOOC(CH2)2CO— or R3-Asp- wherein R3 is hydrogen, an amino acyl residue or an oligopeptidyl residue; and
R2 is an amino acid or an oligopeptide;
with the proviso that compounds represented by SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and SEQ ID NO:4 are excluded.

### Claim 2

A compound of formula IIa or IIb
R4—Y1—(X6)a(X5)b(X4)c(X3)d(X2)eAspTyrX1′(X2′)r(X3′)q(X4′)p(X5′)o(X6′)n—NHCH(R6C(O)—R5 (IIa)
HOOC(CH2)2CO-Tyr-X1′—(X2′)r—(X3′)q—(X4)p—(X5′)o—(X6′)n—NHCH(R6)C(O)—R5 (IIb)
wherein
each of X6, X5, X4, X3, X2, X1′, X2′, X3′, X4′, X5′and X6′ is an amino acid;
Y1 is a linking group or single bond;
R4 is hydrogen, a labelling group, C1-C8alkoxycarbonyl, Ra—C(O)—, Ra—OC(O)— or Ra—NHC(O)— wherein Ra is linear or branched C1-C8alkyl, carboxy-C1-C8alkyl, aryl or aralkyl wherein the aryl group is unsubstituted or substituted by halogen, C1-C4alkyl or C1-C8alkoxy;
R5 is NR7R8 or OR9 wherein R7 and R8 independently are hydrogen, C1-C8alkyl, or R7 and R8 together with the nitrogen atom to which they are attached form a heterocyclic residue, and R9 is hydrogen or C1-C8alkyl;
R6 is an amino acid side chain; and
(a) a, b, c, d and e are 1;
(b) a is 0 and b, c, d and e are 1;
(c) a and b are 0 and c, d and e are 1;
(d) a, b and c are 0 and d and e are 1;
(e) a, b, c and d are 0 and e is 1; or
(f) a, b, c, d and e are 0; and
(a′) n, o, p, q and r are 1;
(b′) n is 0 and o, p, q and r are 1;
(c′) n and o are 0 and p, q and r are 1;
(d′) n, o and p are 0 and q and r are 1;
(e′) n, o, p and q are 0 and r is 1; or
(f′) n, o, p, q and r are 0.

### Claim 3

A compound represented by SEQ ID NO:21, wherein Xaa is H3CC(O)—, and SEQ ID NO:12, wherein Xaa is L(+)-biotinyl-aminohexanoyl and SEQ ID NO: 25 wherein Xaa is L(+)-biotinyl-aminohexanoyl.

### Claim 4

A method of screening for an inhibitor of ZAP-70 or Syk comprising
(a) incubating the ZAP-70 protein and/or the Syk protein with a compound of formula I, adenosine 5′-triphosphate (ATP), and a test compound; and
(b) assessing the ability of the test compound to moderate the interaction of the protein tyrosine kinases Syk and/or ZAP-70 with their substrate compared with the interaction resulting in the absence of the test compound.

### Claim 5

An assay to identify an inhibitor to ZAP-70 and/or Syk comprising
(a) incubating the ZAP-70 protein and/or the Syk protein with a compound of formula I, adenosine 5′-triphosphate (ATP), and a test compound; and
(b) assessing the ability of the test compound to moderate the interaction of the protein tyrosine kinases Syk and/or ZAP-70 with their substrate compared with the interaction resulting in the absence of the test compound.

### Claim 6 (depends on 4, 5)

An immunosuppressant specific for ZAP-70 and/or Syk identified by a method according to claim 4 or an assay according to claim 5.

### Claim 7 (depends on 4, 5)

An immunosuppressant specific for T cells or specific for T cells and NK cells identified by a method according to claim 4 or an assay according to claim 5.

### Claim 8 (depends on 4, 5)

A T cell inhibitor and/or a B cell inhibitor and/or NK cell identified by a method according to claim 4 or an assay according to claim 5.

### Claim 9 (depends on 4, 5)

A modulator of an inflammatory disease identified by a method according to claim 4 or an assay according to claim 5.

### Claim 10 (depends on 4, 5)

A method of inhibiting T-cell function and T-cell proliferation in a subject in need of such inhibition comprising administering to said subject an effective amount of an inhibitor to ZAP-70 and/or Syk identified by a method according to claim 4 or an assay according to claim 5.

### Claim 11 (depends on 4, 5)

A method of inhibiting NK-cell function and NK-cell proliferation in a subject in need of such inhibition comprising administering to said subject an effective amount of an inhibitor to ZAP-70 and/or Syk identified according to claim 4 or an assay according to claim 5.
